{"entity":{"id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","aka":[],"tldr":"A phase 2 trial of Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by Great Novel Therapeutics Biotech & Medicals Corporation, now recruiting.","summary":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) is a phase 2 interventional study registered as NCT05833724 by Great Novel Therapeutics Biotech & Medicals Corporation, with 33 participants planned, started 2024-10-18 and due to reach its primary completion in 2027-06. Interventions recorded: Chidamide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05833724","url":"https://clinicaltrials.gov/study/NCT05833724"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tucidinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05833724","phase":"2","setting":"A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","sponsor":"Great Novel Therapeutics Biotech & Medicals Corporation","enrolled":33,"outcomes":[]},"route":"/trials/nct05833724/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"}]}}